Oculis Holding AG
Lausanne, Vaud, Switzerland · Biopharma, Biotechnology, Health Care
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. The company is focused on advancing late-stage clinical trials for treating conditions such as Dry Eye Disease (DED) and Diabetic Macular Edema (DME).
Key facts
- Headquarters
- Lausanne, Vaud, Switzerland
- Employees
- 60
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (OCS)
- Website
- oculisholding.com
- Company page
Recent activity at Oculis Holding AG
- : Oculis Appoints Björn Tackenberg as Chief Scientific Officer
- : Oculis Holding AG Appoints Katie Kazem as Chief Legal Officer
- : Oculis Holding Appoints Dr. Sharon Klier as Chief Development Officer
- : Oculis Appoints Dr. Sharon Klier as Chief Development Officer
- : Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments
- : Oculis Expands its Executive Leadership Team and Appoints
Leadership
- Björn Tackenberg, Chief Scientific Officer
- Katie Kazem, Chief Legal Officer
- Sharon Klier, Chief Development Officer
- Arshad M. Khanani, Advisory Board Member
- Virginia R. Dean, Chief Human Resources Officer
- Ramin Tadayoni, Chief Scientific Officer
- Rebecca Weil, Chief Commercial Officer
Verified email and direct lines for Oculis Holding AG’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Oculis Holding AG files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Companies similar to Oculis Holding AG
- Altimmune · Biopharma, Biotechnology, Health Care, Therapeutics
- BridgeBio Oncology Therapeutics · Biopharma, Biotechnology, Health Care, Therapeutics
- Zai Lab Limited & MediLink Therapeutics (Suzhou) Ltd · Biopharma, Biotechnology, Health Care, Therapeutics
- TORL BioTherapeutics · Biopharma, Biotechnology, Health Care, Therapeutics
- Kezar Life Sciences · Biopharma, Biotechnology, Health Care, Therapeutics
About Oculis Holding AG: questions and answers
What does Oculis Holding AG do?
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. The company is focused on advancing late-stage clinical trials for treating conditions such as Dry Eye Disease (DED) and Diabetic Macular Edema (DME).
Where is Oculis Holding AG headquartered?
Oculis Holding AG is headquartered in Lausanne, Vaud, Switzerland.
How many employees does Oculis Holding AG have?
Oculis Holding AG has about 60 employees.
What is the latest news on Oculis Holding AG?
On Nov 02, 2026, Oculis Appoints Björn Tackenberg as Chief Scientific Officer
Is Oculis Holding AG a public company?
Yes. Oculis Holding AG is publicly traded under the ticker OCS.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy